Quality by Design Approach for an Immediate Release Tablet

Slides:



Advertisements
Similar presentations
6 th Annual Science and Standards Symposium January 16, 2013 Istanbul Determination of Solubility and Permeability in BCS Erika Stippler, Ph.D. Director.
Advertisements

Current Statistical Issues in Dissolution Profile Comparisons
TABLETS a mixture of powders compacted to form a single, rigid body most common dosage form possess a number of advantages B. AmsdenCHEE 440.
Overview of Guidance Documents and Decision process: Biopharmaceutics Section Mehul Mehta, Ph.D. Director Division of Pharmceutical Evaluation I OCPB,
Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA An Example of Process Understanding Directed Risk Based CMC Regulatory.
World Health Organization
Physical chemical and pharmaceutical-technological properties of powder and granules and their impact on the technology of solid dosage forms. Tablets.
1 TG Dekker – WHO, Malaysia Feb 2005 Comparative dissolution testing and applications World Health Organization Training Workshop on Pharmaceutical Quality,
Documentation of bioequivalence Drs. J. Welink Workshop on WHO prequalification requirements for reproductive health medicines, Jakarta, October 2009.
Achieving and Demonstrating “Quality-by-Design” with Respect to Drug Release/dissolution Performance for Conventional or Immediate Release Solid Oral Dosage.
ACPS Advisory Committee Meeting October , 2002 ACPS Advisory Committee Meeting October , 2002 Scientific Considerations of Polymorphism in.
CHEE 4401 TABLETS u tablet ä a mixture of powders compacted to form a single, rigid body u advantages.
Regulatory requirements Drs. Jan Welink Training workshop: Assessment of Interchangeable Multisource Medicines, Kenya, August 2009.
1-7.The ICH Q8 “Minimal Approach” to Pharmaceutical Development
Formulation factors By Dr. A. S. Adebayo.
Waiver of In Vivo Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System Ajaz S. Hussain,
Evaluation of the Critical Process Parameters in Optimization of Formulation Composition Involving Wet Granulation Feiqian Yu 1, Yusheng Fang 1, Lei Chen.
1 Abu Alam Ph.D. Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 23, 2008.
Bioequivalence of Locally Acting Gastrointestinal Drugs: An Overview
Satish Mallya January 20-22, |1 | 2-3. Pharmaceutical Development Satish Mallya Quality Workshop, Copenhagen May 18-21, 2014 May 18-21,2014.
Dr. Muslim Suardi, MSi., Apt. Faculty of Pharmacy University of Andalas.
Drug Release Specification: In Vivo Relevance Ajaz S. Hussain, Ph.D. Deputy Director, OPS/CDER/FDA.
Introduction What is a Biowaiver?
Tablets coating.
Bioavailability and Bioequivalence General concepts and overview
Solid dosage forms Tablets
Suad Y. Alkarib 1 Dina Elraih 2 Waddah F. Nour 3.
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November |1 | Prequalification programme: Priority.
Topic #2: Quality by Design and Pharmaceutical Equivalence Ajaz S. Hussain, Ph.D. Office of Pharmaceutical Science Center for Drug Evaluation and Research.
BIOPHARMACEUTICS CLASSIFICATION SYSTEM Roma Mathew.
Development and Assessment of Captopril Loaded Matrix-Type Pellets Roderick B. Walker 1, Sandile M.M. Khamanga and Samantha Y. Mukozhiwa Faculty of Pharmacy,
In vitro - In vivo Correlation
1/20 PRESENTED BY BRAHMABHATT BANSARI K. M. PHARM DEPARTMENT OF PHARMACEUTICS AND PHARMACEUTICAL TECHNOLGY L. M. COLLEGE OF PHARMACY.
Brent Owens Davina Felix  The Process of Scientific Inquiry has often left us with headaches  People use acetominophen as a pain reliever but we want.
HOLD-TIME STUDIES.
Biopharmaceutics: Challenges to Pharmaceutical Industry
- Pharmaceutical Equivalence Study
Pharmacology I BMS 242 Lecture II (Continued)
Introduction What is a Biowaiver?
Presentation On Coloring Agent
Doses and Terminology Part 1
Gastrointestinal Absorption: Role of the Dosage Form
ABSTRACT Influence of Different Content of Lactose on the Release of Diclofenac Sodium Formulated in Controlled Release Matrix Tablets Containing.
Biopharmaceutics factors affecting Modified release products
Dissolution testing and in vitro in vivo correlation of conventional and SR preparations Formulation development and optimization is an ongoing process.
TIMERx Oral Controlled-Release Drug Delivery System
Biopharmaceutic Considerations in Drug Product Design
Y. B. Chavan College of Pharmacy,
Pharmacology I BMS 242 Lecture II (Continued)
HHM 5014 NUTRACEUTICAL FORMULATION TECHNOLOGY
Group members: Firdaus | Sofia | Nurainiza | Hafizah
BCS based waiver Harmonization
Office of Pharmaceutical Science, CDER, FDA
Quality Control Requirement
Lab -7- Capsules.
Tablet Dosage Form Lab 1.
HHV ⁵014 NUTRACEUTICAL FORMULATION TECHNOLOGY
Pharmacokinetics: Drug Absorption
Objectives… G&H Meeting February, 2003 Liverpool, UK
Basic Biopharmaceutics
Lab -7- Capsules.
Quality by Design.
Second Level Pharmacy Students
Biopharmaceutics 4th year
Pediatric Formulation Development - A quality perspective
Tablets Lecturer: dr. Asmaa abdelaziz Mohamed Faculty of pharamcay
Solubility of Pills in Simulated Stomach Acids
RingCap Technology Mrs. Maria Saifee Associate Professor,
Formulation factors By Dr. A. S. Adebayo.
3D printing of a wearable personalized oral delivery device: A first-in-human study by Kun Liang, Simone Carmone, Davide Brambilla, and Jean-Christophe.
Presentation transcript:

Quality by Design Approach for an Immediate Release Tablet Venkatesh (‘Venka’) Balasubramanian, Graduate Student, Rutgers University, New Brunswick, New Jersey, USA. Fig 2. Tablet Hardness for method of manufacturing types Abstract Factors Immediate release (IR) tablet is a drug product ingested orally and broken down in the Gastro- Intestinal (GI) tract to provide immediate therapeutic relief from common ailments such as fever, pain, migraine headache etc. Quality by Design (QbD) is about building quality into products and processes during development Drug product tablet manufacturing is either by Dry blend Vs. Wet Granulation process. Tablets are film coated using Hypromellose (‘HPMC ‘) or synthetic polymers such as Polyvinyl alcohol (‘PVA’) and other inactive ingredients such as Talc, Titanium dioxide and colorants (dyes). Polymer coating levels are usually between 1-3% w/w of total tablet weight. Method of Manufacturing: Wet Granulation vs Dry Blend Type: Uncoated tablet vs Coated tablets Coating type: HPMC vs PVA Coating Weight gain: 1% vs 3% Conclusions Uncoated tablets had fastest dissolution and low hardness. Weak core results in visual defects during coating. Wet granulation process has robust core than dry blend HPMC coating has faster dissolution than PVA coating 3% weight gain of HPMC Coated tablets meets acceptance criteria of dissolution (Not more than 15 minutes.) Increase in coating weight leads to increase in hardness and increase in dissolution time. Fig 1. SEM image of Uncoated vs Coated Tablet Surface Results Fastest dissolution was obtained in following order Uncoated core manufactured dry blend Uncoated tablets with wet granulation HPMC based coating system has optimal dissolution time as compared to PVA based 3% coated tablet weight gain had proper physical properties viz. tablet hardness and free from breakages as compared to uncoated tablets. Objective To formulate an immediate release drug product oral solid dosage form (‘tablet’ ) which provides fastest release of drug measured via tablet dissolution (in vitro). Basis: Dissolution in acidic media (pH 2) based on the mean gastric residence time of 30 minutes. References FDA Guidance on Immediate Release Solid Oral Dosage Forms. Scale-up and Post Approval Changes (SUPAC): Chemistry, Manufacturing, and Controls. In vitro dissolution and Bioequivalence Design and Analysis of Experiments, Douglas C. Montgomery, 8th Edition, Wiley

Figure 3. Box Plot of Tablet Hardness across different types of Tablet Coating Click Here to Return Tablet Hardness measured in Kiloponds (kP)

Figure 4. Box Plot of Tablet Dissolution across different types of Tablet Coating Click Here to Return Dissolution media: Acidic (pH 2)